SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 54.58-1.0%Nov 10 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Elmer who wrote (5442)1/15/2002 9:07:13 PM
From: hm  Read Replies (1) of 52153
 
>> success rates in Ph III for double-blind vs. open-label trials <<

In most cases the requirement for substantial evidence of efficacy for drug approval will dictate the need for double-blind Phase III efficacy studies. In all likelihood you would get a better success rate with an open-label Phase III program since open-label trials typically demonstrate higher levels of efficacy than the same drug tested in a double-blind trial.

Hope this helps

HM
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News